GlassScriptPhysician profile
Anne Allen
NPI 1083143226
$2,371.96
in general payments reported to CMS, 2019-2025
23 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $680 · 2023: $1,236 · 2024: $202 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $838.10 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Regeneron Healthcare Solutions, INC. | $339.78 | 2022-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $260.91 | 2022-2023 | Taltz, Olumiant |
| Genzyme Corporation | $186.33 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $139.85 | 2022-2023 | Ilumya, Blu-U, Odomzo |
| Pfizer INC. | $108.06 | 2022-2024 | |
| Incyte Corporation | $106.40 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $101.45 | 2022-2023 | |
| Leo Pharma INC. | $39.76 | 2023 | Adbry |
| Cipher Pharmaceuticals US LLC | $27.49 | 2025 | Natroba, Spinosad |
| Amgen INC. | $27.10 | 2023 | Otezla |
| Kyowa Kirin, INC. | $26.07 | 2025 | |
| Mayne Pharma Commercial LLC | $23.79 | 2023 | |
| Ucb, INC. | $19.20 | 2022 | |
| Blueprint Medicines Corporation | $15.91 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $15.90 | 2023 | Tremfya |
| Epi Health, LLC | $15.27 | 2022 | |
| Galderma Laboratories, L.P. | $13.94 | 2023 | Aklief, Epsolay, Oracea |
| Arcutis Biotherapeutics, INC. | $13.87 | 2024 | Zoryve |
| Nabriva Therapeutics, Plc | $13.49 | 2022 | |
| Avanos Medical | $13.49 | 2024 | On-Q* Pump and Accessories |
| Helsinn Therapeutics (U.S.), INC. | $12.97 | 2022 | |
| Fresenius Kabi USA, LLC | $12.83 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.